By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GenMark Diagnostics said after the close of the market on Thursday that its fourth-quarter revenues more than doubled year over year, led by a 156 percent spike in reagent sales.

For the three months ended Dec. 31, 2010, the Carlsbad, Calif.-based firm posted $787,482 in revenues, up 157 percent from $306,410 a year ago and above a Wall Street forecast of $690,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.